Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Related Citations for PubMed (Select 21149803)

1.

Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis.

Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N, Ramanathan M, Belman A, Chabas D, Gorman MP, Rodriguez M, Rinker JR 2nd, Weinstock-Guttman B; National Network of Pediatric MS Centers of Excellence.

Arch Neurol. 2011 Apr;68(4):437-44. doi: 10.1001/archneurol.2010.325. Epub 2010 Dec 13.

PMID:
21149803
2.

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW.

J Neurol. 2004 Sep;251 Suppl 5:v57-v64. Review.

PMID:
15549357
3.

Current disease-modifying therapies in multiple sclerosis.

Kieseier BC, Hartung HP.

Semin Neurol. 2003 Jun;23(2):133-46. Review. Erratum in: Semin Neurol. 2003 Sep;23(3):343.

PMID:
12894379
4.

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.

Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S.

Adv Ther. 2011 Jan;28(1):51-61. doi: 10.1007/s12325-010-0093-7. Epub 2010 Dec 6.

PMID:
21153000
5.

Treatment of children and adolescents with multiple sclerosis.

Banwell B.

Expert Rev Neurother. 2005 May;5(3):391-401. Review.

PMID:
15938672
6.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
7.

Multiple sclerosis: interferon beta for some serious forms.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):252-7.

PMID:
18092425
8.

Current and future disease-modifying therapies in multiple sclerosis.

Lim SY, Constantinescu CS.

Int J Clin Pract. 2010 Apr;64(5):637-50. doi: 10.1111/j.1742-1241.2009.02261.x. Review.

PMID:
20456216
9.

Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.

Donoghue S, Greenlees C.

Expert Opin Investig Drugs. 2000 Jan;9(1):167-71. Review.

PMID:
11060669
10.

Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

Fox RJ, Bethoux F, Goldman MD, Cohen JA.

Cleve Clin J Med. 2006 Jan;73(1):91-102. Review.

PMID:
16444920
11.

Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Tsai CP, Lee CT.

Clin Drug Investig. 2013 Sep;33(9):647-52. doi: 10.1007/s40261-013-0108-7.

PMID:
23861171
12.

Therapy of multiple sclerosis in children and adolescents.

Tenembaum SN.

Clin Neurol Neurosurg. 2010 Sep;112(7):633-40. doi: 10.1016/j.clineuro.2010.04.015. Epub 2010 May 14. Review.

PMID:
20471159
13.

Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.

Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L, Antonijevic I.

Neurology. 2006 Feb 28;66(4):472-6.

PMID:
16505297
14.

Interferon after 10 years in patients with multiple sclerosis.

Pozzilli C, Prosperini L, Sbardella E, Paolillo A.

Neurol Sci. 2006 Sep;27 Suppl 5:S369-72. Review.

PMID:
16998723
15.
16.

Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.

Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D.

Cardiovasc Ther. 2014 Apr;32(2):33-9. doi: 10.1111/1755-5922.12049.

PMID:
24119301
17.

Long-term follow-up of clinical trials of multiple sclerosis therapies.

Freedman MS.

Neurology. 2011 Jan 4;76(1 Suppl 1):S26-34. doi: 10.1212/WNL.0b013e318205051d. Review.

PMID:
21205679
18.

Current and future role of interferon beta in the therapy of multiple sclerosis.

Farrell RA, Giovannoni G.

J Interferon Cytokine Res. 2010 Oct;30(10):715-26. doi: 10.1089/jir.2010.0089. Review.

PMID:
20874249
19.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
20.

Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.

Pittock SJ, Rodriguez M.

Curr Top Microbiol Immunol. 2008;318:1-17. Review.

PMID:
18219812
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk